Literature DB >> 25267971

Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread.

Anna E Kersh1, Lindsay J Edwards2, Brian D Evavold3.   

Abstract

In this study, we investigate the basis of T cell recognition of myelin that governs the progression from acute symptoms into disease remission, relapse, and chronic progression in a secondary progressive model of demyelinating disease. Until now, the frequency and affinity of myelin-reactive CD4 T cells that elicit relapsing-remitting disease have not been quantified. The micropipette adhesion frequency assay was used to obtain a sensitive and physiologically relevant two-dimensional measurement of frequency and TCR affinity for myelin, as the inherent low affinity does not allow the use of specific peptide:MHC-II tetramers for this purpose. We found the highest affinity and frequency of polyclonal myelin oligodendrocyte glycoprotein-reactive cells infiltrate the CNS during acute disease, whereas affinities during remission, relapse, and chronic disease are not significantly different from each other. Frequency analysis revealed that the vast majority of CNS-infiltrating CD4 T cells are myelin oligodendrocyte glycoprotein reactive at all time points, demonstrating epitope spread is not a predominant factor for disease progression. Furthermore, time points at which mice were symptomatic were characterized by an infiltration of Th17 cells in the CNS, whereas symptom remission showed an enrichment of cells producing IFN-γ. Also, the ratio of regulatory T cells to Foxp3(-) CD4 T cells was significantly higher in the CNS at remission than during acute disease. The results of this study indicate that a high frequency of T cells specific for a single myelin Ag, rather than increased TCR affinity or epitope spread, governs the transition from acute symptoms through remission, relapse, and chronic disease states.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25267971      PMCID: PMC4201951          DOI: 10.4049/jimmunol.1401456

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis.

Authors:  Mandy L Ford; Brian D Evavold
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

Review 2.  The NOD mouse as a model of SLE.

Authors:  P A Silveira; A G Baxter
Journal:  Autoimmunity       Date:  2001       Impact factor: 2.815

3.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

4.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

5.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes.

Authors:  D L Kaufman; M Clare-Salzler; J Tian; T Forsthuber; G S Ting; P Robinson; M A Atkinson; E E Sercarz; A J Tobin; P V Lehmann
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

6.  Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.

Authors:  Adam P Kohm; Jeffrey S McMahon; Joseph R Podojil; Wendy Smith Begolka; Mathew DeGutes; Deborah J Kasprowicz; Steven F Ziegler; Stephen D Miller
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

7.  Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis.

Authors:  Gurumoorthy Krishnamoorthy; Amit Saxena; Lennart T Mars; Helena S Domingues; Reinhard Mentele; Avraham Ben-Nun; Hans Lassmann; Klaus Dornmair; Florian C Kurschus; Roland S Liblau; Hartmut Wekerle
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

8.  T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex.

Authors:  Jarrett J Adams; Samanthi Narayanan; Baoyu Liu; Michael E Birnbaum; Andrew C Kruse; Natalie A Bowerman; Wei Chen; Aron M Levin; Janet M Connolly; Cheng Zhu; David M Kranz; K Christopher Garcia
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

9.  The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells.

Authors:  Richard A O'Connor; Katy H Malpass; Stephen M Anderton
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

10.  Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis.

Authors:  B L McRae; C L Vanderlugt; M C Dal Canto; S D Miller
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  10 in total

1.  Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory.

Authors:  Alexander P R Bally; Yan Tang; Joshua T Lee; Benjamin G Barwick; Ryan Martinez; Brian D Evavold; Jeremy M Boss
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

2.  Cutting Edge: Resident Memory CD8 T Cells Express High-Affinity TCRs.

Authors:  Elizabeth L Frost; Anna E Kersh; Brian D Evavold; Aron E Lukacher
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

3.  Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease.

Authors:  Jennifer D Hood; Veronika I Zarnitsyna; Cheng Zhu; Brian D Evavold
Journal:  J Immunol       Date:  2015-09-18       Impact factor: 5.422

4.  Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.

Authors:  Jinsung Hong; Stephen P Persaud; Stephen Horvath; Paul M Allen; Brian D Evavold; Cheng Zhu
Journal:  J Immunol       Date:  2015-09-02       Impact factor: 5.422

5.  CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection.

Authors:  Rakieb Andargachew; Ryan J Martinez; Elizabeth M Kolawole; Brian D Evavold
Journal:  J Immunol       Date:  2018-05-18       Impact factor: 5.422

6.  NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease.

Authors:  Lori Blanchfield; Joseph J Sabatino; Laurel Lawrence; Brian D Evavold
Journal:  J Immunol       Date:  2017-09-08       Impact factor: 5.422

7.  Low-affinity CD4+ T cells are major responders in the primary immune response.

Authors:  Ryan J Martinez; Rakieb Andargachew; Hunter A Martinez; Brian D Evavold
Journal:  Nat Commun       Date:  2016-12-15       Impact factor: 14.919

8.  CTL-Derived Exosomes Enhance the Activation of CTLs Stimulated by Low-Affinity Peptides.

Authors:  Shu-Wei Wu; Lei Li; Yan Wang; Zhengguo Xiao
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 9.  Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response.

Authors:  Ryan J Martinez; Brian D Evavold
Journal:  Front Immunol       Date:  2015-09-10       Impact factor: 7.561

Review 10.  Relationship of 2D Affinity to T Cell Functional Outcomes.

Authors:  Elizabeth M Kolawole; Tracey J Lamb; Brian D Evavold
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.